Generic

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

By

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

Five things for pharma marketers to know: Tuesday, February 17

Five things for pharma marketers to know: Tuesday, February 17

By

Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

By

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

Five things for pharma marketers to know: Monday, January 26

Five things for pharma marketers to know: Monday, January 26

By

Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.

Supreme Court says Teva MS patent stands (for now)

The ruling stalls generics until at least September.

BI weighs sale of generic business

Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.

FDA appoints Office of Generic Drugs director

FDA has named Kathleen Uhl as permanent director of the Office of Generic Drugs.

Five things for pharma marketers to  know: Thursday, January 8

Five things for pharma marketers to know: Thursday, January 8

By By By

Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.

Five things for pharma marketers to know Wednesday, January 7

Five things for pharma marketers to know Wednesday, January 7

By

India's Patent Office sets aside Humira patent; Gilead acquires fatty liver disease agent; Bloomberg report says M&A activity likely to persist in 2015.

Mylan enters generic Diovan fray

The drugmaker launched four doses of the blood pressure medication.

MM&M's top reads of 2014

MM&M's top reads of 2014

A look at the content that grabbed most reader interest over the past year.

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Bayer loses cancer drug patent fight in India

Court clears the way for a Nexavar generic from Natco

Pfizer's Celebrex slammed by entry of generics

Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.

Five things for pharma marketers to know: Wednesday, December 10

Five things for pharma marketers to know: Wednesday, December 10

By

Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.

Actavis launches generic of Intuniv

The first low-cost version of the Shire ADHD drug benefits as a first-filer.

Five things for pharma marketers to know: Tuesday, November 25

Five things for pharma marketers to know: Tuesday, November 25

By By

AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.

FDA delays rule on generic drug labeling amid controversy

As generic drug use soars, the agency intends to "create parity" in label-change rules for brands and generics.

Five things for pharma marketers to know: Tuesday, November 18

Five things for pharma marketers to know: Tuesday, November 18

By By

Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

By By

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Missing generic hurts Rite Aid

The drugstore chain has lowered its forecast, and generics are just one reason.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.

FDA sanctions don't kill a business

Bloomberg reports that India's Wockhardt has become an M&A target.

FDA sanctions don't kill a business

Bloomberg reports that India's Wockhardt has become an M&A target.

Generic Viagra floods Brazil

The generic ED pills sell for five cents less than Pfizer's branded blue pill, but the undercutting is a bit deeper.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters